Insider Buying: GSK (LON:GSK) Insider Buys £123.55 in Stock

GSK plc (LON:GSK) insider Julie Brown bought 7 shares of the stock in a transaction on Friday, October 9th. The stock was purchased at an average cost of GBX 1,765 per share, with a total value of £123.55.

Julie Brown also recently made the following trade(s):

• On Wednesday, September 9th, Julie Brown purchased 7 shares of GSK stock. The stock was acquired at an average price of GBX 1,803 per share, with a total value of £126.21.

GSK Trading Up 3.6%

Shares of GSK opened at GBX 1,816 on Thursday. GSK plc has a fifty-two week low of GBX 1,592 and a fifty-two week high of GBX 2,282. The company has a market capitalization of £72.77 billion, a PE ratio of 15.42, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. The stock has a fifty day moving average of GBX 1,850.44 and a two-hundred day moving average of GBX 1,928.17. The company has a debt-to-equity ratio of 103.36, a quick ratio of 0.73 and a current ratio of 0.82.

GSK (LON:GSK) last issued its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. As a group, analysts forecast that GSK plc will post 175.98 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on GSK shares. Berenberg Bank raised their price target on GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research note on Tuesday, September 15th. Royal Bank Of Canada restated a “sector perform” rating and issued a GBX 1,975 price target on shares of GSK in a report on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 2,000 price objective on shares of GSK in a research note on Tuesday, September 29th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,500 price objective on shares of GSK in a report on Wednesday, July 29th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of GBX 2,064.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.